Inhibition of interleukin-5 with a monoclonal antibody attenuates allergic inflammation

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 52, Issue 8, 1997, Pages 787-794

  Danzig, M ^a   Cuss, F ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 5; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ALLERGIC REACTION; ALLERGIC RHINITIS; ASTHMA; BRONCHUS HYPERREACTIVITY; EOSINOPHILIA; HUMAN; INFLAMMATION; NONHUMAN; NOSE POLYP; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; REVIEW; SKIN ALLERGY;

EID: 0030840649     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1398-9995.1997.tb02149.x     Document Type: Review

References (102)

1. Holgate ST, Roche WR, Church MK. The role of the eosinophil in asthma. Am Rev Respir Dis 1991;143: S66-S70.
2. Bousquet J, Chang P, Lacosk JV, et al. Eosinophilic inflammation in asthma. New Engl J Med 1990;323:1033-9.
3. Gleich GJ, Kita H, Adolphson CR. Eosinophils. In: Frank MN, Austen KF, Claman HN, Unanue ER, editors. Samter's immunologic diseases. 5th ed. Boston: Little Brown, 1995:205-45.
4. Kay AB. Asthma and inflammation. J Allergy Clin Immunol 1991;87:893-910.
5. Durham SR, Kay AB, Eosinophils, bronchial hyperreactivity and late phase asthmatic reactions. Clin Allergy 1985; 13:411-18.
6. Sur S, Gleich GJ, Swanson MC, et al. Eosinophilic inflammation is associated with the elevation of interleukin-5 in the airways of patients with spontaneous symptomatic asthma. J Allergy Clin Immunol 1995;96:661-8
7. Motojima S, Akutsu I, Fukuda T, Makino S, Takatsu K. Clinical significance of measuring levels of sputum and serum ECP and serum IL-5 in bronchial asthma. Allergy 1993;48 Suppl 17:98-106.
8. Robinson DS, Ying S, Bently AM, et al. Relationships among numbers of bronchoalveolar lavage cells expressing messenger ribonucleic acid for cytokines, asthma symptoms, and airway methacholine responsiveness in asthma. J Allergy Clin Immunol 1993;92:397-403.
9. Corrigan CJ, Haczku A, Gemou-Engesaeth V, et al. CD4 T-lymphocyte activation in asthma is accompanied by increased serum concentrations of interleukin-5. Am Rev Respir Dis 1993;147:540-7.
10. Butterfield JH, Leiferman KM, Gleich GJ. Eosinophil associated diseases. In: Samter's immunologic diseases. 5th ed. Frank MN, Austen KF, Claman HN, Unanue ER, editors. Boston: Little Brown, 1995:501-27.
11. Weller PF. The immunobiology of eosinophils. N Engl J Med 1991;324:1110-14.
12. Kravis L, Kolski G. Unexpected death in childhood asthma: a review. Am J Dis Child 1985;139:558-63.
13. Egan RW, Umland SP, Cuss FM, Chapman RW. Biology of interleukin-5 and its relevance to allergic disease. Allergy 1996;51:71-81.
14. Foster P, Hogan S, Ramsay A, et al. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med 1996; 183:195-201.
15. Kopf M, Brombacher F, Hodgkin P, et al. IL-5 deficient mice have a developmental defect in CD5' B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Immunity 1996;5:81-9.
16. Kung TT, Jones H, Adams GK III, et al. Characterization of a murine model of allergic pulmonary inflammation. Int Arch Allergy Immunol 1994;105:83-90.
17. Kung TT, Stelts DM, Zurcher JA, et al. Involvement of IL-5 in a murine model of allergic pulmonary inflammation: prophylactic and therapeutic effect of an anti-IL-5 antibody. Am J Respir Cell Mol Biol 1995;13:360-5.
18. Murali DS, Kumar A, Choi H, et al. Aspergillus funigatus antigen induced eosinophilia in mice is abrogated by anti-IL-5 antibody. J Leukoc Biol 1993;53:264-7.
19. Mauser PJ, Pitman AM, Witt A, et al. Inhibitory effect of the TRFK-5 anti-IL-5 antibody in a guinea pig model of asthma. Am Rev Respir Dis 1993;148:1623-7.
20. Mauser PJ, Pitman AM, Fernandez X, et al. Effects of an antibody to IL-5 in a monkey model of asthma. Am J Respir Crit Care Med 1995;152:467-72.
21. Egan RW, Wang P, Garlisi C, et al. Mechanism of extended duration of anti-IL-5 antibodies against pulmonary eosinophilia. J Allergy Clin Immunol 1997;99:A496.
22. Coffman R, Seymour B, Hudak S, et al. Antibody to interleukin-5 inhibits helminth induced eosinophilia in mice. Science 1989;245:308-10.
23. Sher A, Coffman R, Hieny S, et al. Ablation of eosinophil and IgE responses with anti-IL-5 or anti-IL-4 antibodies fails to affect immunity against Schistosoma mansoni in the mouse. J Immunol 1990;145:3911-16.
24. Sher A, Coffman R, Hieny S, et al. Inlerleukin-5 is required for blood and tissue eosinophilia but not granuloma formation induced by infection with Schistosoma mansoni. Proc Natl Acad Sci USA 1990;87:61-5.
25. Korenaga M, Hitoshi Y, Yamguchi N, et al. The role of interleukin-5 in protective immunity to Strongyloides venezeulensis infection in mice. Immunology 1991;72: 502-7.
26. Sasaki O, Sugaya H, Ishida K, et al. Ablation of eosinophils with anti-IL-5 antibody enhances the survival of intracranial worms of Angiostrongylus cantonensis in the mouse. Parasite Immunol 1993;15:349-54.
27. Resnick MB, Weller PF. Mechanisms of eosinophil recruitment. Am J Respir Cell Mol Biol 1993;8:349-55.
28. Bradding P, Roberts JA, Britten KM, et al. Interleukin-4, -5, and -6 and tumor necrosis faclor-α in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 1994; 10:471-80.
29. Dubucquoi S, Desreumaux P, Janin A, et al. Interleukin-5 synthesis by eosinophils: association with granules and immunoglobulin-dependent secretion. J Exp Med 1994; 179:703-8.
30. Lopez AF, Shannan MF, Chia M-M, et al. Regulation of human eosinophil production and function by interlcukin-5. Immunol Ser 1992;57:549-71.
31. Abu-Ghazaleh RI, Fujisawa I, Mestecky J, et al. IgA-induced eosinophil degranulation. J Immunol 1989;142: 2393-2400.
32. Egan RW, Cuss FM, Umland SP, et al. Anti-interleukin-5 antibodies as therapeutic agents in asthma and other eosinophilic diseases. In: Henderson B, Bodmer MW, editors. Therapeutic modulation of cytokines. Boca Raton. FL: CRC Press, 1996.
33. Fujisawa I, Abu-Ghazaleh RI, Kita H, et al. Regulalory effect of cytokines on eosinophil degranulation. J Immunol 1990;144:642.
34. Terada N, Konno A, Natori T, et al. Interleukin-5 preferentially recruits eosinophils from vessels in nasal mucosa. Acta Otolaryngol 1993; Suppl 506:57-60.
35. Terada N, Konno A, Tada H, et al. The effect of recombinant human interleukin-5 on eosinophil accumulation and degranulation in human nasal mucosa. J Allergy Clin Immunol 1992;90:160-8.
36. Robinson DS, Hamid Q, Ying S, et al. Predominate TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992;326:298-304.
37. Shaver JR, Zangrilli J, Cho SK, et al. IL-3. IL-5 and GM-CSF have different patterns of production during recovery from IgE-mediated inflammation in allergic asthmatics. Am J Respir Crit Care Med 1996;153:A793.
38. Broide DH, Pain MM, Firestein GS. Eosinophils express interleukin-5 and granulocyte macrophage-colony-stimulating factor mRNA at sites of allergic inflammation in asthmatics. J Clin Invest 1992;90:1414-24.
39. Fukuda T, Nakajima H, Fukushima Y, et al. Detection of interleukin-5 messenger RNA and interleukin-5 protein in bronchial biopsies from asthma by nonradioactive in situ hybridization and immunohistochemistry. J Allergy Clin Immunol 1994;94:584-93.
40. Hamid Q, Azzawi M, Ying S, et al. Interleukin-5 mRNA in mucosal bronchial biopsies from asthmatic subjects. Int Arch Allergy Appl Immunol 1991;94:169-70.
41. Hamid Q, Azzawi M, Ying S, et al. Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma. J Clin Invest 1991;87:1541-6.
42. Wardlaw AJ, Dunnett S, Gleich GJ, et al. Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma: relationship to bronchial hyperreactivity. Am Rev Respir Dis 1988;137:62-9.
43. Ohnishi T, Kita, H, Weiler D, et al. IL-5 is the predominant eosinophil-active cytokine in the antigen-induced pulmonary late-phase reaction. Am Rev Respir Dis 1993;147:901-7.
44. Robinson D, Hamid Q, Bentley A, et al. Activation of CD4+ T cells, increased Th2-type cytokine mRNA expression and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma. J Allergy Clin Immunol 1993;92:313-24.
45. Sedgwick JB, Calhoun WC, Gleich GJ, et al. Immediate and late airway response of allergic rhinitis patients to segmental antigen challenge. Characterization of eosinophil and mast cell mediators. Am Rev Respir Dis 1991;144: 1274-81.
46. Ohnishi T, Sur S, Collins DS, et al. Eosinophil survival activity identified as interleukin-5 is associated with eosinophil recruitment and degranulation and lung injury twenty-four hours after segmental antigen lung challenge. J Allergy Clin Immunol 1993;92:607-15.
47. Zangrilli JG, Shaver JR, Cirelli RA, et al. sVCAM-1 levels after segmental antigen challenge correlate with eosinophil influx, IL-4 and IL-5 production, and the late phase response. Am J Respir Crit Care Med 1995;151:1346-53.
48. Gern JE, Galagan DM, Jarjour NN, et al. Cytokine and rhinovirus 16 (RV16) RNA in the lower airway of experimentally-infected subjects. Am J Respir Crit Care Med 1996;153:A17.
49. Bentley AM, Qiu Meng DS, Robinson DS, et al. Increases in activated T lymphocytes, eosinophils and cytokine mRNA expression for interleukin-5 and granulocyte/macrophage colony-stimulating factor in bronchial biopsies after allergen inhalation challenge in atopic asthmatics. Am J Respir Cell Mol Biol 1993;8:35-42.
50. Walker C, Bauer W, Braun RK, et al. Activated T cells and cytokines in bronchoalveolar lavages from patients with various lung diseases associated with eosinophilia. Am J Respir Crit Care Med 1994;150:1030-48.
51. 1type (interleukin-2 and interferon-γ) cytokines in bronchoalveolar lavage and bronchial biopsies from atopic asthmatic and normal control subjects. Am J Respir Cell Mol Biol 1995;12:477-87.
52. Humbert MJC, Durham SR, Corrigan CJ, et al. Interleukin-4 (IL-4), IL-5 and high affinity IgE receptor expression in bronchial biopsies from atopic and non-atopic asthma: evidence against "intrinsic" asthma being a distinct immunopathological entity. Am J Respir Crit Care Med 1996;153:A413.
53. Walker C, Bauer W, Braun RK, et al. Activated T cells and cytokines in bronchoalveolar lavages from patients with various lung diseases associated with eosinophilia. Am J Respir Crit Care Med 1994;150:1030-48.
54. Walker C, Bode E, Baer L, et al. Allergic and nonallergic asthmatics have distinct patterns of T cell activation and cytokine production in peripheral blood and bronchoalveolar lavage. Am Rev Respir Dis 1992;146:109-15.
55. 1 decline among asthmatics. Am J Respir Crit Care Med 1994;149: A913.
56. Kosmas EN, Polychronaki A, Adamidou A, et al. Theophylline-induced down-regulation of circulating cytokines in young asymptomatic asthmatics. Am J Respir Crit Care Med 1996;153:A805.
57. Shi H, Qin S, Huang G, et al. Infiltration of eosinophils into the asthmatic airways caused by interleukin 5. Am J Respir Cell Mol Biol 1997;16:220-4.
58. Martin RJ, Cicutto LC, Smith HR, et al. Airways inflammation in nocturnal asthma. Am Rev Respir Dis 1991;143: 351-7.
59. Jarjour NN, Busse WW. Cytokines in bronchoalveolar lavage fluid of patients with nocturnal asthma. Am J Respir Crit Care Med 1995;152:1474-7.
60. Wilson SJ, Kraft M, Martin R, et al. Lung immunostaining for IL-4 and IL-5 in nocturnal asthma. Am J Respir Crit Care Med 1996;153:A879.
61. Rasp G, Thomas P. Interleukin-5 release in late antigeninduced nasal secretion is associated with eosinophil activation. J Allergy Clin Immunol 1995;95:258.
62. Sim TC, Grant JA, Hilsmeir KA, et al. Detection of proinflammatory cytokines in the nasal secretions of allergic subjects following antigen challenge. Am J Respir Crit Care Med 1994;149:339-44.
63. Jorgensen RK, Gleich GJ, Kita H, et al. Topical glucocorticoid treatment of ragweed hay fever. I. Effects of IgE and IgA antibody production. J Allergy Clin Immunol 1997;99:S360.
64. Dunnette SL, Kita H, Reed CE, et al. Topical glucocorticoid treatment of ragweed hay fever. II. Relationship of eosinophil-derived neurotoxin (EDN) and IL-5 to disease severity. J Allergy Clin Immunol 1997;99:S124.
65. Djukanovic R. Nasal polyps - a model of chronic respiratory mucosal inflammation. Clin Exp Allergy 1995;25: 582-5.
66. Ohno I, Nitta Y, Yamauchi K, et al. Eosinophils as a potential source of platelet-derived growth factor B-chain (PDGF-B) in nasal polyps and bronchial asthma. Am J Respir Cell Mol Biol 1995;13:639-47.
67. Xaubet A, Mullol J, Lopez E, et al. Comparison of the role of nasal polyps and normal nasal mucosal epithelial cells on in vitro eosinophil survival mediation by GM-CSF and inhibition by dexamethasone. Clin Exp Allergy 1994; 24:307-17.
68. Rudak C, Reeker HC, Wagenmann M, et al. IL-5 dominates in nasal polyps. J Allergy Clin Immunol 1996;97:192.
69. Dater I, Bachert C. Localization of interleukin-5 (IL-5) in RNA in eosinophils of nasal polyps by in situ hybridization. J Allergy Clin Immunol 1996;97:276.
70. Wagenmann M, Dater I, Rudak C, et al. Interleukin-5 protein and mRNA are increased in nasal polyps. J Allergy Clin Immunol 1996;97:300.
71. Simon HU, Yousefi S, Weber M, et al. Direct demonstration of delayed eosinophil apoptosis as a mechanism to cause tissue eosinophilia. Am J Respir Crit Care Med 1996; 153:A56.
72. Lee CH, Rhee CS, Min YG. Cytokine gene expression in nasal polyp. J Allergy Clin Immunol 1996;97:192.
73. Kay AB, Ying S, Varney V, et al. Messenger RNA expression of the cytokine gene cluster, interleukin 3 (IL-3), IL-4, IL-5, and granulocyte/macrophage colony-stimulating factor, in allergen-induced late-phase cutaneous reactions in atopic subjects. J Exp Med 1991;173:775-8.
74. Vowels BR, Rook AH, Cussin M, et al. Expression of interleukin-4 and interleukin-5 mRNA in developing cutaneous late-phase reactions. J Allergy Clin Immunol 1995; 96:92-6.
75. Parrott CM, Graif Y, Lessin SR, et al. Quantitative analysis of cytokines in cutaneous late phase (LPR) allergic reactions: a role for IL-5 in the developing LPR. J Allergy Clin Immunol 1997;99:S170.
76. Spergel JM, Boyce J, Schneider LC. Hypereosinophilia, elevated IgE and interleukin-5 levels in neonatal atopic dermatitis. J Allergy Clin Immunol 1997;99:S322.
77. Taha RA, Leung DYM, Boguniewicz M, et al. IL-4 and IL-5 receptor mRNA expression in acute and chronic atopic dermatitis. J Allergy Clin Immunol 1997;99:S331.
78. Allen JN, Liao Z, Wewers MD, et al. Detection of IL-5 and IL-1 receptor antagonist in bronchoalveolar lavage fluid in acute eosinophilic pneumonia. J Allergy Clin Immunol 1996;97:1366-74.
79. Butterfield JH, Leiferman KM, Abrams J, et al. Elevated serum levels of interleukin-5 in patients with the syndrome of episodic angioedema and eosinophilia. Blood 1992; 79:688-92.
80. Hamilos DL, Plout M, Leung DYM, et al. GM-CSF. IL-5 and RANTES mRNA expression and protein levels in chronic hyperplastic sinusitis with nasal polyposis. J Allergy Clin Immunol 1997;99:S130.
81. Ichinohe S, Kobayashi H, Yamauchi K, et al. RSV infection caused the increase of histamine, eosinophil cationic protein, and interleukin-8 in nasopharyngeal fluid. Am J Respir Crit Care Med 1996;153:A502.
82. Tsunoda M, Guevarra L, Tollerud DJ. Serum cytokine levels, cigarette smoking and ethnicity among healthy men. Am J Respir Crit Care Med 1996;153:A103.
83. Saetta M, DiStefano A, Maestrelli P, et al. Airway eosinophilia and expression of interleukin-5 protein: in asthma and exacerbations of chronic bronchitis. Clin Exp Allergy 1996;26:766-74.
84. Pisani CVH, Korvach JS, Kita H, et al. Administration of interleukin-2 (IL-2) results in increased plasma concentrations of IL-5 and eosinophilia in patients with cancer. Blood 1991;78:1538-44.
85. Lazarus DS, Kurnick JT, Kradin RL. Alterations in pulmonary function in cancer patients receiving adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2. Am Rev Respir Dis 1990;141:193-8.
86. Altman A, Coggeshall KM, Mustelin T. Molecular events mediating T cell activation. Adv Immunol 1990;48:227-360.
87. Rolfe FG, Hughes JM, Armour CL, et al. Inhibition of interleukin-5 gene expression by dexamethasone. Immunology 1992;77:494-9.
88. Van Straaten JFM, Dokler WHA, Stulp BK, et al. The regulation of interleukin-5 and interleukin-3 gene expression in human T cells. Cytokine 1994;6:229-34.
89. Travenier J, Devos R, Cornelis S, et al. A human high affinity interleukin-5 receptor (IL-5R) is composed of an IL-5 specified a chain and β chain shared with the receptor for GM-CSF. Cell 1991;66:1175-84.
90. Yamaguchi S, Nagai H, Tanaka H, et al. Time course study for antigen-induced airway hyperreactivity and the effect of soluble IL-5 receptor. Life Sci 1994;54:471-5.
91. Elliott MJ, Maini RN, Feldmann M, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor A (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105.
92. Stack WA, Mann SD, Roy AJ, et al. Randomized controlled trial of CDP571 antibody to tumour necrosis factor-a in Crohn's disease. Lancet 1997;349:521-4.
93. Murata Y, Takaki S, Migita M, et al. Molecular cloning and expression of the human interleukin-5 receptor. J Exp Med 1992;175:341-51.
94. Kruse N, Tony HP, Sebald W. Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid replacement. EMBO J 1992;11:3237-44.
95. Darnell JE Jr, Kerr AM, Stark GR. JAK-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;262: 1415-20.
96. Bloemen P, Henricks R Nijkamp F. Cell adhesion molecules and asthma. Clin Exp Allergy 1997;27:128-41.
97. Lukacs NW, Standiford TJ, Chensue SW, et al. C-C chemokine-induced eosinophil chemotaxis during allergic airway inflammation. J Leukoc Biol 1996;60:573-8.
98. Adair JR. Engineering antibodies for therapy. Immunol Rev 1992;130:5-40.
99. Johnson KS, Chiswell DJ. Human antibody engineering. Curr Opin Struct Biol 1993;3:564-71.
100. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/ neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-44.
101. Kuus-Reichel K, Grauer LS, Karvodin LM et al. Will immunogenicity limit the use of, efficacy, and future development of therapeutic monoclonal antibodies? Clin Diagn Lab Immunol 1994;1:365-72.
102. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1225-7.